Axsome Therapeutics Inc [AXSM] stock is trading at $91.93, down -1.87%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AXSM shares have gain 14.85% over the last week, with a monthly amount glided 2.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on December 31, 2024, when Mizuho reiterated its Outperform rating and also revised its price target to $122 from $124. Previously, Wells Fargo started tracking the stock with Overweight rating on September 03, 2024, and set its price target to $140. On August 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $106 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $130 on July 22, 2024. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $115 on April 29, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on March 19, 2024, and assigned it a price target of $108. In a note dated February 06, 2024, UBS initiated an Buy rating and provided a target price of $111 on this stock.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $64.11 and $105.00 over the past year. Currently, Wall Street analysts expect the stock to reach $133 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $91.93 at the most recent close of the market. An investor can expect a potential return of 44.68% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 338.46M for the trailing twelve months, which represents a growth of 81.27%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.91%, Pretax Profit Margin comes in at -0.92%, and Net Profit Margin reading is -0.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -2.34 and Total Capital is -0.84. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 90.87 points at the first support level, and at 89.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 93.95, and for the 2nd resistance point, it is at 95.96.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 2.44. As well, the Quick Ratio is 2.37, while the Cash Ratio is 1.67. Considering the valuation of this stock, the price to sales ratio is 13.16, the price to book ratio is 47.93.
Transactions by insiders
Recent insider trading involved Saad Mark E, Director, that happened on Sep 11 ’24 when 11016.0 shares were sold. Director, Saad Mark E completed a deal on Sep 11 ’24 to buy 11016.0 shares. Meanwhile, Chief Operating Officer Jacobson Mark L. sold 47739.0 shares on Aug 09 ’24.
